10170 CHURCH RANCH WAY, WESTMINSTER, CO
Todd Edwards Joins Oruka Therapeutics as Chief Commercial Officer
Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Annual Meeting of Stockholders - Election of Class II Directors
First Amendment to IL-23 License Agreement with Paragon Therapeutics
Certain Financial and Operating Data for First Quarter
Reg. FD, Other Events
Annual Report to Security Holders
Director Resignation and Appointment at Oruka Therapeutics
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Prospectus filed pursuant to Rule 424(b)(7)